JFG
CHRS icon

Jefferies Financial Group’s Coherus Oncology CHRS Stock Holding History

Jefferies Financial Group’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$353K Hold
252,000
– – ﹤0.01% 1339
2026
Q1 		$426K Sell
252,000
-143,190
-36% -$254K ﹤0.01% 1273
2025
Q4 		$561K Buy
395,190
+69,565
+21% +$101K ﹤0.01% 1301
2025
Q3 		$534K Buy
325,625
+8,000
+3% +$8.9K ﹤0.01% 1062
2025
Q2 		$232K Hold
317,625
– – ﹤0.01% 1092
2025
Q1 		$256K Buy
317,625
+10,000
+3% +$11.5K ﹤0.01% 1297
2024
Q4 		$425K Buy
307,625
+25,000
+9% +$28K ﹤0.01% 1157
2024
Q3 		$294K Buy
282,625
+86,000
+44% +$118K ﹤0.01% 1121
2024
Q2 		$340K Hold
196,625
– – ﹤0.01% 1081
2024
Q1 		$470K Buy
196,625
+113,000
+135% +$278K ﹤0.01% 1077
2023
Q4 		$278K Buy
83,625
+43,000
+106% +$115K ﹤0.01% 1386
2023
Q3 		$152K Buy
+40,625
New +$188K ﹤0.01% 1393
2023
Q2 		– Sell
-130,625
Closed -$893K – 1720
2023
Q1 		$893K Buy
130,625
+106,000
+430% +$823K 0.01% 934
2022
Q4 		$195K Buy
+24,625
New +$189K ﹤0.01% 1303

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Jefferies Financial Group's CHRS Position: Q2 2026 in Review

Jefferies Financial Group held its Coherus Oncology (CHRS) position steady in Q2 2026 at 252,000 shares worth $353K. The position accounts for ﹤0.01% of the portfolio, ranked #1339.

Jefferies Financial Group first reported a position in CHRS in Q4 2022 and has held it in 14 quarters since. The position peaked at $893K in Q1 2023. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Jefferies Financial Group held 252,000 shares of Coherus Oncology worth $353K as of Q2 2026.
  • Jefferies Financial Group left its Coherus Oncology share count unchanged in Q2 2026.
  • Coherus Oncology made up ﹤0.01% of Jefferies Financial Group's portfolio in Q2 2026, its #1339 holding.
  • Jefferies Financial Group first reported a position in Coherus Oncology in Q4 2022 and has held it in 14 quarters since.
  • Jefferies Financial Group's Coherus Oncology position peaked at $893K in Q1 2023.
  • 146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.